These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

818 related items for PubMed ID: 12617376

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
    Wade DT, Makela P, Robson P, House H, Bateman C.
    Mult Scler; 2004 Aug; 10(4):434-41. PubMed ID: 15327042
    [Abstract] [Full Text] [Related]

  • 3. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003 Aug; 4(5):306-9. PubMed ID: 12952500
    [Abstract] [Full Text] [Related]

  • 4. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
    Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M.
    Mult Scler; 2004 Aug; 10(4):417-24. PubMed ID: 15327040
    [Abstract] [Full Text] [Related]

  • 5. Sativex for the management of multiple sclerosis symptoms.
    Perras C.
    Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
    [Abstract] [Full Text] [Related]

  • 6. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C, Davies P, Mutiboko IK, Ratcliffe S, Sativex Spasticity in MS Study Group.
    Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.
    Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ.
    Mult Scler; 2004 Aug; 10(4):425-33. PubMed ID: 15327041
    [Abstract] [Full Text] [Related]

  • 10. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ, Nurmikko TJ, Young CA.
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [Abstract] [Full Text] [Related]

  • 11. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM.
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [Abstract] [Full Text] [Related]

  • 12. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
    Rog DJ, Nurmikko TJ, Friede T, Young CA.
    Neurology; 2005 Sep 27; 65(6):812-9. PubMed ID: 16186518
    [Abstract] [Full Text] [Related]

  • 13. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG, Henze T, Essner U, Trompke C, Vila Silván C.
    Int J Neurosci; 2020 Dec 27; 130(12):1199-1205. PubMed ID: 32065006
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.
    Berman JS, Symonds C, Birch R.
    Pain; 2004 Dec 27; 112(3):299-306. PubMed ID: 15561385
    [Abstract] [Full Text] [Related]

  • 15. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
    Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S.
    J Neurol; 2013 Apr 27; 260(4):984-97. PubMed ID: 23180178
    [Abstract] [Full Text] [Related]

  • 16. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT.
    J Pain Symptom Manage; 2013 Aug 27; 46(2):207-18. PubMed ID: 23141881
    [Abstract] [Full Text] [Related]

  • 17. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
    Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, Rivas GR, Holland RM, Muhleisen P, Norberg MM, Booth J, McGregor IS.
    JAMA Psychiatry; 2014 Mar 27; 71(3):281-91. PubMed ID: 24430917
    [Abstract] [Full Text] [Related]

  • 18. Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial.
    Suraev A, McCartney D, Marshall NS, Irwin C, Vandrey R, Grunstein RR, D'Rozario AL, Gordon C, Bartlett D, Hoyos CM, McGregor IS.
    Psychopharmacology (Berl); 2024 Sep 27; 241(9):1815-1825. PubMed ID: 38758300
    [Abstract] [Full Text] [Related]

  • 19. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
    Syed YY, McKeage K, Scott LJ.
    Drugs; 2014 Apr 27; 74(5):563-78. PubMed ID: 24671907
    [Abstract] [Full Text] [Related]

  • 20. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG.
    JAMA; 2020 Dec 01; 324(21):2177-2186. PubMed ID: 33258890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.